An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer

Cancer Biology and Therapy

Volumn 17, Issue 4, 2016, Pages 346-354

  Li, Hongwen ^a   Yu, Chao ^b   Jiang, Jing ^c   Huang, Changjiang ^b   Yao, Xuejing ^a   Xu, Qiaoyu ^b   Yu, Fang ^b   Lou, Liguang ^d   Fang, Jianmin ^a,e,f  

^a TONGJI UNIVERSITY   (China)

^b RemeGen   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e SOOCHOW UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

Author keywords

Antibody drug conjugate; gastric cancer; HER2; monomethyl auristatin E; target therapy

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERTUZUMAB; HERTUZUMAB MONOMETHYL AURISTATIN E CONJUGATE; LAPATINIB; MONOCLONAL ANTIBODY; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN; ERBB2 PROTEIN, MOUSE; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NCI N87 CELL LINE; NONHUMAN; RECEPTOR AFFINITY; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, NUDE; OLIGOPEPTIDES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959043553     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1139248     Document Type: Article

References (45)

1. P.Karimi, F.Islami, S.Anandasabapathy, N.D.Freedman, F.Kamangar. Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention. Cancer Epidem Biomar 2014; 23:700-13; PMID:24618998; http://dx.doi.org/10.1158/1055-9965.EPI-13-1057
2. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.1017/S0009840X13002084
3. S.Shimoyama Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). Mol Clin Oncol 2014; 2:175-81; PMID:24649329; http://dx.doi.org/ 10.3892/mco.2013.218
4. I.B.Weinstein, A.K.Joe. Mechanisms of disease: Oncogene addiction–a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448-57; PMID:16894390; http://dx.doi.org/10.1038/ncponc0558
5. M.Yan, B.A.Parker, R.Schwab, R.Kurzrock. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014; 40:770-80; PMID:24656976; http://dx.doi.org/10.1016/j.ctrv.2014.02.008
6. N.Gao, H.Xu, C.Liu, H.Xu, G.Chen, X.Wang, Y.Li, Y.Wang. Nestin: predicting specific survival factors for breast cancer. Tumour Biol 2014; 35:1751-5; PMID:24443256; http://dx.doi.org/10.1007/s13277-013-1548-7
7. M.D.Marmor, K.B.Skaria, Y.Yarden. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58:903-13; PMID:14967450; http://dx.doi.org/10.1016/j.ijrobp.2003.06.002
8. T.Helikar, N.Kochi, B.Kowal, M.Dimri, M.Naramura, S.M.Raja, V.Band, H.Band, J.A.Rogers. A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells. PloS One 2013; 8:e61757; PMID:23637902; http://dx.doi.org/10.1371/journal.pone.0061757
9. Y.Zhang, L.Opresko, H.Shankaran, W.B.Chrisler, H.S.Wiley, H.Resat. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 2009; 10:78; PMID:19878579; http://dx.doi.org/10.1186/1471-2121-10-78
10. B.Beltran Garate, A.Yabar Berrocal. [HER2 expression in gastric cancer in Peru]. Rev Gastroenterol Peru 2010; 30:324-7; PMID:21263759
11. G.Z.Yu, Y.Chen, J.J.Wang. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135:1331-9; PMID:19337752; http://dx.doi.org/10.1007/s00432-009-0574-8
12. Z.Zhu, J.Wang, Z.Sun, X.Sun, Z.Wang, H.Xu. Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PloS One 2013; 8:e62365; PMID:23658725; http://dx.doi.org/10.1371/journal.pone.0062365
13. Y.Y.Janjigian, D.Werner, C.Pauligk, K.Steinmetz, D.P.Kelsen, E.Jager, H.M.Altmannsberger, E.Robinson, L.J.Tafe, L.H.Tang, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Annal Oncol 2012; 23:2656-62; PMID:2268179; http://dx.doi.org/10.1093/annonc/mds104
14. W.Q.Sheng, D.Huang, J.M.Ying, N.Lu, H.M.Wu, Y.H.Liu, J.P.Liu, H.Bu, X.Y.Zhou, X.Du. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Annal Oncol 2013; 24:2360-4; PMID:23788757; http://dx.doi.org/10.1093/annonc/mdt232
15. C.Graziano HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today 1998; 12(1), 14-6; PMID:10187049
16. Y.Kurokawa, N.Sugimoto, H.Miwa, M.Tsuda, S.Nishina, H.Okuda, H.Imamura, M.Gamoh, D.Sakai, T.Shimokawa, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014; 110:1163-8; PMID:24473399; http://dx.doi.org/10.1038/bjc.2014.18
17. Y.J.Bang, E.Van Cutsem, A.Feyereislova, H.C.Chung, L.Shen, A.Sawaki, F.Lordick, A.Ohtsu, Y.Omuro, T.Satoh, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi.org/10.1016/S0140-6736(10)61121-X
18. X.Ding, X.Qu, Y.Fan, X.Che, J.Qu, L.Xu, J.Liu, Y.Liu. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. Anti-Cancer Drug 2014; 25:315-22; PMID:24300914; http://dx.doi.org/10.1097/CAD.0000000000000048
19. K.Shiraishi, K.Mimura, S.Izawa, A.Inoue, S.Shiba, T.Maruyama, M.Watanabe, Y.Kawaguchi, M.Inoue, H.Fujii, et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gast Cancer 2013; 16:571-80; PMID:23187882; http://dx.doi.org/10.1007/s10120-012-0219-5
20. D.Sakai, T.Satoh, Y.Kurokawa, T.Kudo, K.Nishikawa, Y.Oka, T.Tsujinaka, T.Shimokawa, Y.Doki, H.Furukawa. A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). Jpn J Clin Oncol 2013; 43:838-40; PMID:23852648; http://dx.doi.org/10.1093/jjco/hyt083
21. G.H.Dai, Y.Shi, L.Chen, Y.L.Lv, M.Zhong. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepato-Gastroenterol 2012; 59:2439-44; PMID:22534547; http://dx.doi.org/10.5754/hge12166
22. B.K.Ko, S.Y.Lee, Y.H.Lee, I.S.Hwang, H.Persson, J.Rockberg, C.Borrebaeck, D.Park, K.T.Kim, M.Uhlen, et al. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. Mol Oncol 2014; PMID:25306393; http://dx.doi.org/10.1016/j.molonc.2014.09.007
23. M.Tanner, A.I.Kapanen, T.Junttila, O.Raheem, S.Grenman, J.Elo, K.Elenius, J.Isola. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Therapeut 2004; 3:1585-92; PMID:15634652
24. C.T.Chan, M.Z.Metz, S.E.Kane. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005; 91:187-201; PMID:15868447; http://dx.doi.org/10.1007/s10549-004-7715-1
25. S.Panowksi, S.Bhakta, H.Raab, P.Polakis, J.R.Junutula. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014; 6:34-45; PMID:24423619; http://dx.doi.org/10.4161/mabs.27022
26. J.Loke, J.N.Khan, J.S.Wilson, C.Craddock, K.Wheatley. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Annal Hematol 2015; 94:361-73; PMID:25284166; http://dx.doi.org/10.1007/s00277-014-2218-6
27. FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. Oncology (Williston Park) 2011; 25:904; PMID:22010386
28. A.Ballantyne, S.Dhillon. Trastuzumab emtansine: first global approval. Drugs 2013; 73:755-65; PMID:23620199; http://dx.doi.org/10.1007/s40265-013-0050-2
29. A.Mullard. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12:329-33; PMID:23629491; http://dx.doi.org/10.1038/nrd4009
30. D.Ma, C.E.Hopf, A.D.Malewicz, G.P.Donovan, P.D.Senter, W.F.Goeckeler, P.J.Maddon, W.C.Olson. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12:2591-6; PMID:16638870; http://dx.doi.org/10.1158/1078-0432.CCR-05-2107
31. Z.H.Li, Q.Zhang, H.B.Wang, Y.N.Zhang, D.Ding, L.Q.Pan, D.Miao, S.Xu, C.Zhang, P.H.Luo, et al. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. Invest New Drug 2014; 32:75-86; PMID:23903896; http://dx.doi.org/10.1007/s10637-013-9995-y
32. H.P.Gerber, M.Kung-Sutherland, I.Stone, C.Morris-Tilden, J.Miyamoto, R.McCormick, S.C.Alley, N.Okeley, B.Hayes, F.J.Hernandez-Ilizaliturri, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009; 113:4352-61; PMID:19147785; http://dx.doi.org/10.1182/blood-2008-09-179143
33. D.Dornan, F.Bennett, Y.Chen, M.Dennis, D.Eaton, K.Elkins, D.French, M.A.Go, A.Jack, J.R.Junutula, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009; 114:2721-9; PMID:19633198; http://dx.doi.org/10.1182/blood-2009-02-205500
34. D.E.Afar, V.Bhaskar, E.Ibsen, D.Breinberg, S.M.Henshall, J.G.Kench, M.Drobnjak, R.Powers, M.Wong, F.Evangelista, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Therapeut 2004; 3:921-32; PMID:15299075
35. V.A.DiPippo, W.C.Olson, H.M.Nguyen, L.G.Brown, R.L.Vessella, E.Corey. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. The Prostate 2015; 75:303-13; PMID: 25327986; http://dx.doi.org/ 10.1002/pros.22916
36. S.J.Scales, N.Gupta, G.Pacheco, R.Firestein, D.M.French, H.Koeppen, L.Rangell, V.Barry-Hamilton, E.Luis, J.Chuh, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Therapeut 2014; 13:2630-40; PMID:25249555; http://dx.doi.org/10.1158/1535-7163.MCT-14-0487-T
37. X.Yao, J.Jiang, X.Wang, C.Huang, D.Li, K.Xie, Q.Xu, H.Li, Z.Li, L.Lou, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat 2015; 153:123-33; PMID:26253944; http://dx.doi.org/10.1007/s10549-015-3503-3
38. N.M.Okeley, S.C.Alley, P.D.Senter. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol Oncol Clin North America 2014; 28:13-25; PMID:24287064; http://dx.doi.org/10.1016/j.hoc.2013.10.009
39. M.Barok, M.Tanner, K.Koninki, J.Isola. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306:171-9; PMID:21458915; http://dx.doi.org/10.1016/j.canlet.2011.03.002
40. H.-L.Roche A study of trastuzumab emtansine versus taxane in patients with advanced gastric Cancer 2014.
41. H.-L.Roche A combination study of Kadcyla (Trastuzumab Emtansine) and capecitabine in patients with HER2-Positive metastatic breast cancer and patients with HER2-Positive locally advanced/ metastatic gastric. Cancer. 2014.
42. D.Lu, H.A.Burris, 3rd, B.Wang, E.C.Dees, J.Cortes, A.Joshi, M.Gupta, J.H.Yi, Y.W.Chu, T.Shih, et al. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metabol 2012; 13:911-22; PMID:22475266; http://dx.doi.org/10.2174/138920012802138688
43. J.Lu, J.Pu, X.Lu, H.Fu, M.Wei, G.Yang. beta-Diketone modified trastuzumab: a next-generation of Herceptin for resistant breast cancer cells? Med Hypotheses 2012; 79:602-4; PMID:22922054; http://dx.doi.org/10.1016/j.mehy.2012.07.030
44. Y.Abdiche, D.Malashock, A.Pinkerton, J.Pons. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Analyt Biochem 2008; 377:209-17; PMID:18405656; http://dx.doi.org/10.1016/j.ab.2008.03.035
45. M.S.Sutherland, R.J.Sanderson, K.A.Gordon, J.Andreyka, C.G.Cerveny, C.Yu, T.S.Lewis, D.L.Meyer, R.F.Zabinski, S.O.Doronina, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006; 281:10540-7; PMID:16484228; http://dx.doi.org/10.1074/jbc.M510026200